Fig. 5: mTORC1 signature in Still’s disease correlates with disease severity and treatment response.
From: mTORC1 links pathology in experimental models of Still’s disease and macrophage activation syndrome
a Cluster plot of gene set enrichment analysis comparing healthy controls and patients with sJIA and AOSD using in publicly available transcriptomic dataset. b Gene set enrichment plot of Hallmark mTORC1 gene set and (c) calculation of mTOR gene set score from healthy controls (n = 22), sJIA patients at baseline (n = 82) and sJIA patients 3 days after canakinumab treatment (n = 69). d Stratification of mTOR gene score before treatment and 3 days after canakinumab based on clinical response after 24 weeks. Clinical response was stratified according to American College of Rheumatology (ACR) Score: ACR 0/Non-responders (NR, n = 10), ACR30 (n = 6), ACR50 (n = 11), ACR70 (n = 16), ACR90 (n = 8), ACR100 (n = 11). e Levels of glycolytic enzymes from serum proteomics analysis of healthy controls (n = 21), sJIA patients with inactive (n = 27) or active disease (n = 24), and sJIA patients with MAS (n = 10). Transcriptomic data for (b–d) are derived from GEO data series GSE80060 while proteomics data in (e) were derived from Chen et al.20. Statistical analyses (all two-sided): permutation test (a, b), Mann–Whitney U test (c, e), Kruskal–Wallis one-way analysis of variance (d). Median and error bars representing interquartile range are displayed in (c–e). Source data are provided as a Source Data file.
